Lemaitre Vascular, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Petusky from Barrington maintained a Buy rating on the stock and has a $95.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Petusky’s rating is based on several positive indicators for Lemaitre Vascular. The company has demonstrated strong pricing power, with a significant portion of its organic growth attributed to price increases, and this trend is expected to continue into 2026. Additionally, Lemaitre has made substantial progress in achieving MDR compliance in the EU, which positions it well for market share gains as competitors struggle with compliance costs.
Moreover, Lemaitre’s financial position is robust, with substantial cash reserves that could be used for strategic acquisitions, enhancing its growth prospects. The recent commercial launch of XenoSure in China and potential regulatory approvals for other products also present future growth opportunities. These factors collectively support the Buy rating, with a price target of $95 based on projected financial performance.
According to TipRanks, Petusky is a 2-star analyst with an average return of 0.3% and a 43.48% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Option Care Health, Haemonetics, and Lifecore Biomedical.